Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series
1 Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, USA
2 Department of Dermatology, Royal Prince Alfred Hospital, New South Wales, Australia
BMC Dermatology 2005, 5:9 doi:10.1186/1471-5945-5-9Published: 18 August 2005
Severe psoriasis vulgaris can be extremely difficult to treat in some patients, even with the newer biological therapies available today.
We present two patients with severe chronic plaque psoriasis who received numerous systemic anti-psoriatic therapies with varied results. Both responded well to initial treatment with efalizumab (anti-CD11a), but then experienced a flare of their disease after missing a dose. However, after disease stablization, both patients responded well to re-introduction of efalizumab, one patient requiring concurrent treatment with infliximab (anti-TNF-α).
These cases are presented to characterize this "flare" reaction, and to inform health care providers that efalizumab can still be administered after disease flare, and again may be a successful therapy.